Evidence map›Paper›PMID 35916103›Full record

ArticleMedical physics2022

Developing breast lesion detection algorithms for digital breast tomosynthesis: Leveraging false positive findings.

Md Belayat Hossain, Robert M Nishikawa, Juhun Lee

Open access · greenAbstract read
In one paragraph

Article in Medical physics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Md Belayat HossainDepartment of Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Robert M NishikawaDepartment of Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Juhun LeeDepartment of Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
University of Pittsburgh · US

Funding

Developing a personalized breast cancer screening tool using sequential mammogramsR37CA248207 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LEE, JUHUN · 2020 to 2025
$2.5M
NCI NIH HHS R37 CA248207NIH HHS R37 CA248207
6 · The paper itself

Abstract

backgroundDue to the complex nature of digital breast tomosynthesis (DBT) in imaging techniques, reading times are longer than 2D mammograms. A robust computer-aided diagnosis system in DBT could help radiologists reduce their workload and reading times. PURPOSE: The purpose of this study was to develop algorithms for detecting biopsy-proven breast lesions on DBT using multi-depth level convolutional models and leveraging non-biopsied samples. As biopsied positive samples in a lesion dataset are limited, we hypothesized that false positive (FP) findings by detection algorithms from non-biopsied benign lesions could improve detection algorithms by using them as data augmentation. APPROACH: We first extracted 2D slices from DBT volumes with biopsy-proven breast lesions (cancer and benign), with non-biopsied benign lesions (actionable), and for controls. Then, to provide lesion continuity along the z-direction, we combined a lesion slice with its immediate adjacent slices to synthesize 2.5-dimensional (2.5D) images of the lesion by assigning them into R, G, and B color channels. We used 224 biopsy-proven lesions from 39 cancer and 62 benign patients from a DBTex challenge dataset of 1000 scans. We included the 2.5D images of immediate neighboring slices from the lesion's center to increase the number of training samples. For lesion detection, we used the YOLOv5 algorithm as our base network. We trained a baseline algorithm (medium-depth level) using biopsied samples to detect actionable FPs in non-biopsied images. Afterward, we fine-tuned the baseline model on the augmented image set (actionable FPs added). For lesion inferencing, we processed the DBT volume slice-by-slice to estimate bounding boxes in each slice, and then combined them by connecting bounding boxes along the depth via volumetric morphological closing. We trained an additional model (large) with deeper-depth levels by repeating the above process. Finally, we developed an ensemble algorithm by combining the medium and large detection models. We used the free-response operating characteristic curve to evaluate our algorithms. We reported mean sensitivity per FPs per DBT volume only for biopsied views and sensitivity at 2-false positives per image (2FPI) for all views. However, due to the limited accessibility to the truth of the challenge validation and test datasets, we used sensitivity at 2FPI for statistical evaluation.

resultsFor the DBTex independent validation set, the medium baseline model achieved a mean sensitivity of 0.627 FPs per DBT volume, and a sensitivity of 0.640 at 2FPI. After adding actionable FP lesions, the model had an improved 2FPI of 0.769 over the baseline (p-value = 0.013). Our ensemble algorithm with multi-depth levels (medium + large) achieved a mean sensitivity of 0.815 FPs per DBT volume and an improved sensitivity at 2FPI of 0.80 over the baseline (p-value < 0.001) on the validation set. Finally, our ensemble model achieved a mean sensitivity of 0.786 FPs per DBT volume and a sensitivity of 0.743 at 2FPI on the DBTex independent test set.

conclusionsOur results show that actionable FP findings hold useful information for lesion detection algorithms, and our ensemble detection model with multi-depth levels improves lesion detection performance.

Indexed as

BreastBreast NeoplasmsAlgorithmsDiagnosis, Computer-AssistedFemaleHumansMammographybreast cancercomputer-aided detectiondeep learningdigital breast tomosynthesislesion detection

Identifiers

PMID35916103
PMCPMC10156088
OpenAlexW4289517972

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.